HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)
Richard A. Jenkins, Ph.D
John Satterlee, Ph.D.
Raul N. Mandler, Ph.D.
Peer review contact:
Peer review contact information will appear in the applicant's eRA Commons account approximately 2 weeks after the submission date.
Financial and grants management
The HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional) program provides funding for NIH high priority research relevant to drug misuse and HIV/AIDS. Research priorities revolve around the National Institute on Drug Abuse Seek, Test, Treat, and Retain framework, and include reducing health disparities in the incidence of new HIV infections or in treatment outcomes of those living with HIV/AIDS. Populations of interest include urban, suburban, and rural drug users; populations at elevated risk for HIV, such as men who have sex with men; and people in rural areas who use opioids and injection drugs.
Eligible applicants include:
- Higher education institutions
- Public/state controlled institutions
- Private institutions
- Nonprofit organizations
- With 501(c)(3) status
- Without 501(c)(3) status
- Native American tribal organizations
- Faith-based or community-based organizations
- Regional organizations
- City or township
- Special districts
- Federally recognized Indian/Native American tribal governments
- Indian/Native American tribal governments (other than federally recognized)
- Eligible agencies of the federal government
- U.S. territory or possession
- Independent school districts
- Public housing authorities
- Indian housing authorities
- Non-domestic entities
- Small businesses
- For-profit organizations
Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period is 5 years.
For complete information about funding programs, including your application status, please contact funders directly. Summaries are provided for your convenience only. RHIhub does not take part in application processes or monitor application status.